123843-65-2Relevant articles and documents
QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS
-
Page/Page column 176-177, (2020/04/25)
The present application relates to novel quinazoline compounds as inhibitors of type I receptor tyrosine kinases, the pharmaceutical compositions comprising one or more of the compounds and salts thereof as an active ingredient, and the use of the compounds and salts thereof in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals and especially in humans.
Synthesis of 5-heterocyclic substituted quinazolin-4-ones via 2-aminobenzonitrile derivatives
Fray, M. Jonathan,Allen, Paul,Bradley, Paul R.,Challenger, Clare E.,Closier, Michael,Evans, Tim J.,Lewis, Mark L.,Mathias, John P.,Nichols, Carly L.,Po-Ba, Yvonne M.,Snow, Hayley,Stefaniak, Mark H.,Vuong, Hannah V.
, p. 489 - 494 (2007/10/03)
Two routes to prepare a series of six 5-heterocyclic substituted 2-chloro-7-methoxyquinazolin-4-ones are described, where the heterocycle is a substituted or unsubstituted 1-pyrazolyl, 5-pyrazolyl or 2-thiazolyl group. Both routes proceeded via key 2-amin
Carboxylate derivatives comprising an ether group and liquid crystal composition comprising the same
-
, (2008/06/13)
A compound represented by the following general formula (I), a liquid crystal composition comprising the same, and a liquid crystal element using this liquid crystal composition. (wherein B1 and B2 represent independently a trans-1,4-cyclohexylene group o